The 36-Patient Acne Laser Pilot Published in 2026: Safety and Monitoring Questions for Adults With Persistent Acne

The July 2026 pilot tested intense pulsed light (IPL), a broad-spectrum light treatment, pulsed dye laser (PDL), a blood-vessel-targeting laser, and Q-switched Nd:YAG 1064-nm laser, a short-pulse pigment-targeting laser, in 36 patients with moderate-to-severe inflammatory acne. No device reduced lesion counts or severity scores more than the others, and adverse effects were described as minimal. For adults with persistent acne, the useful question is not which pilot device won. The useful question is what hurts, what to watch on the skin, and how laser options compare with guideline care and drug monitoring.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

What did the 36-patient trial test?
Did any device clear more acne?
Which option hurt less during treatment?
What should you monitor after treatment?
How do lasers fit adult acne care?

What did the 36-patient trial test?

The trial was a three-arm randomized comparison in moderate-to-severe inflammatory acne. Inflammatory acne means red papules, pustules, and deeper tender bumps. The U.S.

National Library of Medicine PubMed listing dates the Lasers in Medical Science paper to July 10, 2026 in the PubMed trial record. Each arm received one energy approach: IPL, PDL, or Q-switched Nd:YAG 1064-nm laser. Researchers tracked lesion counts and severity scores during treatment. They also tracked disability with the Cardiff Acne Disability Index, which measures how acne affects daily life.

Did any device clear more acne?

No arm showed a clear efficacy lead. The PubMed listing reports no significant differences among the three arms in lesion counts or severity scores at any treatment session, with P-values from 0.06 to 0.92.

Disability scores moved in a more positive direction. Cardiff Acne Disability Index scores fell significantly from baseline to two weeks after the final treatment across participants. That change reflects lived burden rather than proof that one device works better.

Which option hurt less during treatment?

Pain differed more than lesion response. In that comparison the Q-switched Nd:YAG group reported less procedural pain than the IPL or PDL groups, according to the Biology Insights safety summary in the Biology Insights safety summary.

Adverse effects across all three arms were described as minimal in the same summary. For a reader choosing care, less pain with similar short-term lesion change matters. It affects whether a person completes a course and how much recovery time daily life allows.

What should you monitor after treatment?

Watch the treated skin closely for the first days and weeks. A separate acne energy device shows why monitoring matters. Cutera's 1726-nm AviClear received FDA 510(k) clearance March 24, 2022 as the first energy device for mild, moderate, and severe acne, Cutera Inc. reports, by targeting sebaceous glands and suppressing sebum.

Cutera warns that AviClear can cause several local effects needing post-treatment skin monitoring, detailed in the Cutera product safety information. Ask your clinic what to expect and when to call: Take dated photos in the same light. Note pain level, new spots, blisters, color change, and fever. Seek prompt care for infection signs, severe blistering, rapidly spreading redness, or vision or eye symptoms after facial treatment.

discomfort, redness, swelling, dryness, or transient acne flare
blisters, crusting or scabbing
darker or lighter spots, texture change, or altered hair growth
spreading pain, pus, fever, worsening swelling, or open sores that do not heal
any scar-like thickening or lasting color change

How do lasers fit adult acne care?

Lasers remain an uncertain routine option. The American Academy of Dermatology 2024 acne guideline finds evidence insufficient to recommend laser and light devices for routine acne. It calls for large prospective multicenter randomized double-blinded placebo-controlled trials.

That caution matters for persistent adult acne, which often continues beyond adolescence especially in women. Drug paths carry their own monitoring load. Isotretinoin is contraindicated in pregnancy and distributed under FDA's iPLEDGE REMS to reduce embryo-fetal toxicity, so pregnancy prevention and laboratory follow-up remain mandatory.